-
Enfortumab vedotin, sold
under the
brand name Padcev, is an antibody-drug
conjugate used for the
treatment of
urothelial cancer. It is a nectin-4-directed...
-
checkpoint inhibitors,
followed by the
antibody drug
conjugate therapy enfortumab vedotin.
Around 500,000
people are
diagnosed with
bladder cancer each...
-
addition to
brentuximab vedotin,
Seattle Genetics'
product pipeline includes enfortumab vedotin,
being co-developed with
Astellas Pharma,
tisotumab vedotin, being...
- lymphoma". FDA.
Retrieved 2019-06-14. "FDA
grants accelerated approval to
enfortumab vedotin-ejfv for
metastatic urothelial cancer". FDA. 2019-12-18. Retrieved...
- is also
known as
Tumor suppressor in lung
cancer 1 (TSLC1). Nectin-4 :
Enfortumab vedotin-ejfv was
approved by the FDA in 2019; it is a Nectin-4-directed...
-
tisotumab vedotin Examples:
Sofituzumab vedotin Polatuzumab vedotin (RG7596)
Enfortumab vedotin Pinatuzumab vedotin Lifastuzumab vedotin Brentuximab vedotin Glembatumumab...
-
Overactive bladder (OAB) – US only;
marketed by
Pfizer Outside of US.
Padcev (
enfortumab vedotin) -
Bladder cancer Prograf (tacrolimus) –
Prevention of post-transplant...
-
Cosibelimab Daratumumab Dinutuximab beta
Dostarlimab Durvalumab Elotuzumab Enfortumab vedotin Epcoritamab Inotuzumab ozogamicin Ipilimumab Isatuximab Loncastuximab...
-
Mogamulizumab L01FX10
Olaratumab L01FX11
Bermekimab L01FX12
Tafasitamab L01FX13
Enfortumab vedotin L01FX14
Polatuzumab vedotin L01FX15
Belantamab mafodotin L01FX16...
- the
original on 11
August 2020.
Retrieved 5
October 2020. "Padcev ejfv-
enfortumab vedotin injection, powder, lyophilized, for solution". DailyMed. Archived...
